The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 Weeks

The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).

Start Date06 Mar 2026

Sponsor / Collaborator

GSK Plc

NCT07177339

/ RecruitingPhase 3

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation

Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

Start Date20 Oct 2025

Sponsor / Collaborator

GSK Plc

NCT06979323

/ RecruitingPhase 3

The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study

Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

Start Date03 Jun 2025

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Depemokimab

100 Translational Medicine associated with Depemokimab

100 Patents (Medical) associated with Depemokimab

Literatures (Medical) associated with Depemokimab

01 Feb 2026·ADVANCES IN THERAPY

Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2

Article

Author: Blackorby, Allison ; Leslie, Anna ; Vichiendilokkul, Anna ; Jackson, Daniel J ; Cornet, Marjolein ; Karkoszka, Natalia ; Bourdin, Arnaud ; Howarth, Peter ; Fujieda, Shigeharu

INTRODUCTION:

Depemokimab, the first ultra-long-acting respiratory biologic, is under investigation for diseases with underlying type 2 (T2) inflammation. Subcutaneous depemokimab 100 mg was efficacious in patients with T2 asthma characterized by blood eosinophil count and in chronic rhinosinusitis with nasal polyps (CRSwNP) when administered twice-yearly in four Phase III randomized, double-blind, placebo-controlled studies (SWIFT-1/-2 and ANCHOR-1/-2, respectively). This pooled analysis examined the safety and tolerability of subcutaneous depemokimab 100 mg versus placebo in patients with T2 asthma and in CRSwNP.

METHODS:

Adverse event (AE) frequency, severity, time-to-onset, duration, and relative risk (RR) were evaluated for depemokimab 100 mg and placebo administered subcutaneously every 26 weeks for 52 weeks using pooled SWIFT-1/-2 and ANCHOR-1/-2 data. The impact of immunogenicity on safety was also evaluated.

RESULTS:

Overall, 1290 patients from the four studies were included in the safety analysis population (773 [60%] received depemokimab; 517 [40%] received placebo). On-treatment AEs were reported by 73% and 78% of patients in the depemokimab and placebo groups, respectively; the majority were mild or moderate in intensity and transient, with similar durations between treatment groups. Serious AEs (SAEs; 5% and 10%, with depemokimab and placebo, respectively), and discontinuations due to AEs (< 1% and 1%, respectively) were infrequent. No fatal AEs or treatment-related SAEs (per investigator assessment) were reported. RRs (vs. placebo) were similar for all common on-treatment AEs except asthma and back pain, which occurred less frequently in the depemokimab group compared with the placebo group. Antidrug antibodies and neutralizing antibodies occurred infrequently, and no association between antidrug antibody status and depemokimab efficacy was identified.

CONCLUSIONS:

In these studies, twice-yearly depemokimab 100 mg was generally well tolerated by patients with T2 asthma or CRSwNP over the 52-week treatment period, supporting the safety of the first ultra-long-acting biologic for these diseases.

CLINICAL TRIAL IDENTIFIER(S):

NCT04719832/NCT04718103/NCT05274750/NCT05281523.

01 Feb 2026·ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Drop ANCHOR with depemokimab or sail to the WAYPOINT with tezepelumab

Article

Author: Greig, Robert ; Suter, Philipp ; Lipworth, Brian J

01 Dec 2025·Current Opinion in Allergy and Clinical Immunology

Depemokimab: a new long-acting anti-IL5 treatment for severe asthma and chronic rhinosinusitis with nasal polyps

Review

Author: Bernstein, David I

Purpose of review:

Clinical data are reviewed pertaining to depemokimab, the first extended life anti-IL5 mAb, for treating severe eosinophilic asthma. This molecule was engineered through amino acid modification (YTE mutation) of the Fc region. This modification increases Fc receptor affinity and enables antibody recycling, thereby greatly extending serum half-life and will allow a dosing duration of 26 weeks.

Recent findings:

Phase 1 and 3 clinical studies have demonstrated that depemokimab maintains drug concentrations and reduces peripheral eosinophils over a single 26-week dosing interval. A 52-week double-blinded, placebo-controlled (DBPC) Phase 3 study of patients with severe eosinophilic asthma demonstrated that depemokimab reduced annualized asthma exacerbations by 54% compared with placebo, the primary efficacy outcome. No significant differences between active and placebo arms were detected for secondary endpoints (e.g., symptoms, FEV1 and quality of life). Results of a noninferiority study comparing depemokimab, benralizumab and mepolizumab are pending. In a DBPC trial of chronic rhinosinusitis with nasal polyps (CRSwNP), depemokimab was also effective in reducing nasal polyp endoscopy scores and nasal obstruction.

Summary:

Depemokimab could offer patients with severe persistent asthma a more convenient add-on treatment option than existing shorter acting biologics and thereby improve overall adherence.

News (Medical) associated with Depemokimab

15 Apr 2026

·adimab.com

Adimab Collaborator GSK Receives Additional Marketing Approval for Depemokimab

Lebanon, New Hampshire – April 15, 2026 – Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, congratulates GSK plc for recently receiving approvals by the European Commission (EC) and China’s National Medical Products Administration (NMPA) for depemokimab. This adds to recent marketing approvals in the United States, Japan, and the United Kingdom. Depemokimab is the first ultra-long-acting biologic product approved for use in its indicated conditions and was developed internally by GSK with an extended half-life and engineered high binding affinity to enable twice-yearly dosing, as demonstrated in GSK’s pivotal trials. To support in the engineering of the molecule, GSK internalized Adimab’s proprietary yeast-based technology, enabling in-house antibody discovery, optimization, production, and characterization on any target of GSK’s choosing. GSK’s research team used the Adimab Platform for depemokimab, a product tailored to meet GSK’s target product profile, including low picomolar affinity. GSK continues to use the Adimab platform to support other internal programs. “Depemokimab is the first approved product to emerge from our Platform Transfer collaborations, further validating this portion of our business model. Fittingly, GSK was our first Platform Transfer collaborator, and we congratulate them on this tremendous success,” said Philip T. Chase, Chief Executive Officer of Adimab. “Depemokimab is just one example of GSK’s adoption of the Adimab technology to pursue innovative therapeutic products,” added Eric Krauland, President and Chief Scientific Officer of Adimab. “GSK’s use of the platform, exemplified through ongoing investment in the Adimab team’s expertise and the use of Adimab's technological advances such as new library diversities, has translated into other GSK clinical programs that aim to make a real difference for patients.” Adimab’s other Platform Transfer collaborators include Biogen, Lilly, Merck, Novo Nordisk, and Takeda. Each Platform Transfer collaborator has been enabled, through training at Adimab and their own site, to operate Adimab’s proprietary platform independently. Further, each Platform Transfer collaborator has their own unique diversity, ensuring non-overlapping outputs. The Adimab technology can be used on any biologic target, in any format, and in any therapeutic area, allowing flexibility from discovery through engineering and generation of multispecifics. Support is always available, including access to Adimab scientists, biannual technology summits, and regular updates to strains, libraries, and in silico tools. Other commercial products containing molecules from Adimab include: Innovent’s TYVYT® (sintilimab injection), a PD1 program approved in China for the treatment of multiple cancers. Innovent’s SINTBILO® (tafolecimab injection), a PCSK9 program approved in China for the treatment of adult patients with primary hypercholesterolemia and mixed dyslipidemia. IASO Bio’s FUCASO® (equecabtagene autoleucel), a BCMA CAR-T program approved in China for the treatment of patients with multiple myeloma. Invivyd’s PEMGARDA™ (pemivibart), a SARS-CoV-2 monoclonal antibody authorized for prophylactic emergency use in the United States to prevent COVID-19 infection. Sun Pharma’s UNLOXCYT™ (cosibelimab), a PD-L1 program approved in the United States for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma. There are numerous additional Adimab-associated programs that are currently in Phase II or Phase III (pivotal) trials. The total number of Adimab-associated clinical programs initiated by our collaborators has now reached 90. About Adimab Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. Our suite of technologies includes naïve discovery from synthetic libraries in yeast or B cells (mice, llamas, and humans), antibody engineering and optimization, bi- and multispecific antibody engineering, and a portfolio of proprietary CD3 and CD28 antibodies with complementary heterodimerization mutations that are licensed non-exclusively for bi- and multispecific applications. Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 140 pharmaceutical and biotechnology companies, generating more than 650 therapeutic programs, 90 clinical programs, and 6 approved products. The Adimab technology has been transferred and implemented at GSK, Biogen, Novo Nordisk, Merck, Lilly, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Alnylam, Bristol Myers Squibb, Innovent, Novartis, Regeneron, Vertex and others. Adimab has also partnered with many early-stage venture-backed companies, including Dragonfly, NextPoint Therapeutics, Santa Ana Bio, Tizona, Kelonia, and others, as well as mid-size public biopharmaceutical companies such as Alector, Cullinan Therapeutics, Scholar Rock, and others. Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.

Drug ApprovalPhase 3Phase 2

08 Apr 2026

·allsci.com

China approves GSK’s Exdensur for chronic rhinosinusitis with nasal polyps in adults

GSK announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as add-on therapy with intranasal corticosteroids for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) whose disease is inadequately controlled by systemic corticosteroids and/or surgery. The approval positions depemokimab as the first ultra-long-acting biologic available in China for this indication, and follows the NMPA’s recent clearance of the same molecule for severe eosinophilic asthma in patients aged 12 years and older. Exedensur has now secured CRSwNP approvals across major markets including the EU, UK, Japan, and China, but not in the US, where the FDA has approved the molecule only for severe asthma and issued a Complete Response Letter (CRL) for CRSwNP, stating that the filing failed to provide “adequate evidence” of efficacy. The China CRSwNP indication covers adults who have not achieved adequate disease control despite systemic corticosteroid use or surgical intervention. Depemokimab is administered as an add-on to maintenance intranasal corticosteroids, with dosing at six-monthly intervals — a schedule that distinguishes it from other approved biologics in this class, which require monthly or biweekly administration. The NMPA decision was supported by data from the ANCHOR-1 and ANCHOR-2 Phase III trials, which enrolled 528 adults with inadequately controlled CRSwNP, bilateral nasal polyps, and an endoscopic bilateral nasal polyp score of 5 or higher. All participants had prior CRSwNP surgery, prior systemic corticosteroid use, or intolerance to systemic corticosteroids. Patients received depemokimab or placebo every 26 weeks alongside standard-of-care intranasal corticosteroids. At 52 weeks, depemokimab produced statistically significant reductions in nasal polyp score versus placebo: treatment differences of −0.7 (95% CI −1.1 to −0.3; p<0.001) in ANCHOR-1 and −0.6 (95% CI −1.0 to −0.2; p=0.004) in ANCHOR-2. Nasal obstruction scores over weeks 49–52 also improved, with treatment differences of −0.23 (p=0.047) and −0.25 (p=0.025) in the two trials respectively. The tolerability profile was comparable to placebo plus standard of care. Full results were published in The Lancet and presented at the 2025 AAAAI/WAO Joint Congress. CRSwNP is driven by chronic inflammation of the nasal lining, producing soft tissue polyps that cause nasal obstruction, loss of smell, facial pain, sleep disturbance, and recurrent infections. According to GSK, approximately half of patients with CRSwNP remain uncontrolled on existing therapies, and up to 85% have underlying type 2 inflammation — a cytokine-mediated endotype associated with more severe disease and tissue remodelling. Depemokimab targets interleukin-5 (IL-5), a cytokine central to eosinophil survival and activation within the type 2 inflammatory pathway. Its engineered extended half-life enables the twice-yearly dosing interval, which GSK the company said represents a potential adherence advantage over currently available options. The CRSwNP biologic landscape has expanded considerably since dupilumab (Dupixent, Regeneron/Sanofi) received the first approval in this indication in 2019, targeting the shared IL-4/IL-13 receptor component. Omalizumab (Xolair, Genentech/Novartis), an anti-IgE antibody, followed with a CRSwNP approval in 2020, and mepolizumab (Nucala, GSK) — which shares depemokimab’s IL-5 target — was approved in 2021. Most recently, tezepelumab (Tezspire, Amgen/AstraZeneca), which acts upstream by targeting the alarmin TSLP, received US FDA approval for CRSwNP in October 2025. Exdensur (depemokimab) holds CRSwNP approvals in the EU, UK, Japan, and now China; its FDA status for this indication has not been confirmed in available sources, though the molecule received US approval for severe asthma. Within this field, depemokimab’s twice-yearly dosing interval is a pharmacokinetic differentiator relative to agents requiring monthly or biweekly injections. Whether that attribute translates into meaningful adherence or outcome differences in clinical practice remains to be established in real-world settings. GSK is also evaluating depemokimab across a broader type 2 inflammatory disease spectrum: Phase III trials are underway in eosinophilic granulomatosis with polyangiitis (OCEAN trial) and hypereosinophilic syndrome (DESTINY trial), alongside the ENDURA-1, ENDURA-2, and VIGILANT programs in uncontrolled moderate-to-severe COPD with type 2 inflammation — an indication where biologics have historically faced limited success but where biomarker-enriched patient selection may improve the probability of benefit. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Drug ApprovalClinical Result

30 Mar 2026

·www.gsk.com

Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)

Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP Approval based on ANCHOR trials showing clinically meaningful and statistically significant improvements in nasal polyp size and nasal obstruction Patients with CRSwNP continue to face debilitating daily symptoms, underscoring need for novel treatments GSK plc (LSE/NYSE: GSK) today announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. This follows the NMPA’s recent approval for Exdensur as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients aged 12 years and older.1 The approval of Exdensur in CRSwNP is based on data from the ANCHOR-1 and ANCHOR-2 phase III trials, which showed an improvement (reduction) from baseline in nasal polyp score (scale: 0-8) at 52 weeks [treatment difference (95% confidence interval) p-value: ANCHOR-1 -0.7 (-1.1, -0.3) p<0.001 and ANCHOR-2 -0.6 (-1.0, -0.2) p=0.004] and in nasal obstruction verbal response scale (scale: 0-3) over weeks 49-52 [ANCHOR-1 -0.23 (-0.46, <0.00) p=0.047 and ANCHOR-2 -0.25 (-0.46, -0.03) p=0.025].4 Across these trials, depemokimab was well-tolerated, with patients experiencing a similar rate and severity of side effects as those receiving placebo plus standard of care.2 Kaivan Khavandi, SVP, R&D Head Respiratory, Immunology & Inflammation (RI&I), and Head of Translational & Development Sciences, GSK, said: “Given the continued unmet need amongst patients with CRSwNP, today’s approval of Exdensur could redefine care by protecting from the debilitating symptoms of this disease in just two doses a year. This builds on Exdensur’s recent approval in severe asthma, which means more patients in China could have access to this first and only ultra-long-acting biologic.” Almost half of all patients with CRSwNP remain uncontrolled and up to 85% have underlying type 2 inflammation, which is associated with more severe disease.3-5 An ultra-long-acting therapeutic option that provides sustained suppression of type 2 inflammation could support these patients who continue to face daily symptoms. Exdensur has also been approved in the US and China for the treatment of severe asthma, as well as in Japan, the EU, and UK for the treatment of severe asthma and CRSwNP.1,6-9 About CRSwNP CRSwNP is caused by inflammation of the nasal lining that can lead to soft tissue growths, known as nasal polyps.3,10 People with CRSwNP experience symptoms such as nasal obstruction, loss of smell, facial pain, sleep disturbance, infections and nasal discharge that can significantly affect their emotional and physical well-being.3,10 Similar to asthma, the majority of cases of CRSwNP are driven by chronic type 2 inflammation, which is strongly associated with comorbidities, more severe disease, recurring symptoms and tissue remodelling.3,5,10-13 About Exdensur (depemokimab) Exdensur is the first ultra-long-acting biologic being evaluated for certain respiratory diseases with underlying type 2 inflammation. It combines high interleukin-5 (IL-5) binding affinity and high potency with an extended half-life to enable twice-yearly dosing. IL-5 is a key cytokine in type 2 inflammation.2 For product and important safety information please consult the country’s relevant summary of product characteristics. The EU product information is available at: https://www.ema.europa.eu/en/medicines/human/EPAR/exdensur The US product information is available at: EXDENSUR-PI-PIL.PDF About the ANCHOR phase III trials Full results from the ANCHOR trials were presented at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and published in The Lancet.2,14 ANCHOR-1 included 143 patients in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm; in ANCHOR-2, 129 patients were included in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm. All 528 patients had inadequately controlled CRSwNP, including nasal polyps in both nasal cavities (an endoscopic bilateral NPS ≥5), and had either undergone previous surgery for CRSwNP, had received previous treatment with SCS or were intolerant to SCS. Patients received depemokimab or placebo at six-monthly intervals (26 weeks) in addition to SOC (maintenance intranasal corticosteroids).2 About the depemokimab development programme Depemokimab is currently being evaluated in phase III trials for the treatment of other diseases with underlying type 2 inflammation, including OCEAN for eosinophilic granulomatosis with polyangiitis (EGPA) and DESTINY for hyper eosinophilic syndrome (HES).15,16 GSK has also initiated the ENDURA-1, ENDURA-2 and VIGILANT phase III trials assessing the efficacy and safety of depemokimab as an add-on therapy in patients with uncontrolled moderate to severe COPD with type 2 inflammation.17-19 About GSK in respiratory GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care, and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, GSK is focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim of modifying the underlying disease dysfunction and preventing progression. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025. References You might also like

Phase 3Clinical ResultDrug Approval

100 Deals associated with Depemokimab

External Link

KEGG	Wiki	ATC	Drug Bank
D12169	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eosinophilic Asthma	China	GlaxoSmithKline Trading Services Ltd.	25 Mar 2026
Severe asthma	United States	GlaxoSmithKline LLC	16 Dec 2025
Asthma	United Kingdom	GSK Plc	15 Dec 2025
Chronic rhinosinusitis with nasal polyps	United Kingdom	GSK Plc	15 Dec 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis, Chronic	Phase 3	United States	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	China	GSK Plc	20 Oct 2025
Pulmonary Disease, Chronic Obstructive	Phase 3	United States	GSK Plc	20 Jun 2025
Pulmonary Disease, Chronic Obstructive	Phase 3	China	GSK Plc	20 Jun 2025
Pulmonary Disease, Chronic Obstructive	Phase 3	Japan	GSK Plc	20 Jun 2025
Pulmonary Disease, Chronic Obstructive	Phase 3	Belgium	GlaxoSmithKline Research & Development Ltd.	20 Jun 2025
Pulmonary Disease, Chronic Obstructive	Phase 3	Canada	GlaxoSmithKline Research & Development Ltd.	20 Jun 2025
Pulmonary Disease, Chronic Obstructive	Phase 3	Chile	GlaxoSmithKline Research & Development Ltd.	20 Jun 2025
Pulmonary Disease, Chronic Obstructive	Phase 3	Colombia	GlaxoSmithKline Research & Development Ltd.	20 Jun 2025
Pulmonary Disease, Chronic Obstructive	Phase 3	Croatia	GlaxoSmithKline Research & Development Ltd.	20 Jun 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05274750 (ANCHOR-1, AAAAI2026)	Phase 3	Chronic rhinosinusitis with nasal polyps	154	Depemokimab 100mg	oysnjuudau(xdpwwmgxsl) = lelbrmxuca byjsibmjjr (dcgcmvaysl, 0.18) View more	Positive	27 Feb 2026
				Placebo	oysnjuudau(xdpwwmgxsl) = aocamrssdk byjsibmjjr (dcgcmvaysl, 0.19) View more
NCT05243680 (AGILE, AAAAI2026)	Phase 3	Asthma	629	Depemokimab (Prior Depemokimab)	tdporicaji(mvrtwdnqwf) = dqmiajxipe ekyeldpyze (eecmmrwopt ) View more	Positive	27 Feb 2026
				Depemokimab (Prior Placebo)	tdporicaji(mvrtwdnqwf) = kxamsanqkn ekyeldpyze (eecmmrwopt ) View more
NCT05243680 (AGILE, CTgov)	Phase 3	Asthma	641	Placebo+GSK3511294 (Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study)	jbokstjwmf = safyvfimvt xnfkewmlzw (yucnjitulf, gshulrpzkl - lotinysjsb) View more	-	15 Jan 2026
				GSK3511294 (GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study)	jbokstjwmf = cmdctfshmf xnfkewmlzw (yucnjitulf, hwutcsxnjt - xlwkgpmdoa) View more
NCT05274750 (ANCHOR-1, CTgov)	Phase 3	Chronic rhinosinusitis with nasal polyps	276	Depemokimab (GSK3511294) (Depemokimab)	pcwkcyfdlo(xcfksnegsw) = kkywzkiupd divdikgazh (wcbfjnkspl, 0.14) View more	-	03 Dec 2025
				Placebo (Placebo)	pcwkcyfdlo(xcfksnegsw) = dqldbykydf divdikgazh (wcbfjnkspl, 0.15) View more
NCT05281523 (ANCHOR-2, CTgov)	Phase 3	Chronic rhinosinusitis with nasal polyps	264	Depemokimab (GSK3511294) (Depemokimab)	yubmjdpvnt(rtsqmozdca) = nevqlonqbv iuartjcvpe (hbmsnkssye, 0.14) View more	-	09 Sep 2025
				Placebo (Placebo)	yubmjdpvnt(rtsqmozdca) = sztqghqxkw iuartjcvpe (hbmsnkssye, 0.15) View more
NCT05281523 \| NCT05274750 (ANCHOR-1, Company_Website \| Literature) Manual	Phase 3	Chronic rhinosinusitis with nasal polyps	528	Depemokimab + SOC (ANCHOR-1)	hmrzbuzhrp(rscqctosmq) = ofwjjjuyjj auxeoyzgli (ymusrywthp ) Met View more	Positive	01 Mar 2025
				Placebo + SOC (ANCHOR-1)	eflpbpijlw(zgjitokrxk) = wgtnermjkz ywnqdgcqgr (nhzaqncfsv )
NCT04719832 (SWIFT-1, CTgov)	Phase 3	Asthma	395	Placebo (Placebo)	fbofbbvzor(fxhaymxbvz) = qleogjjxkd pgfwkgeqvx (dzoolgbdoo, ehilgobxgr - zeovpgipee) View more	-	17 Dec 2024
				GSK3511294 (Depemokimab) (GSK3511294)	fbofbbvzor(fxhaymxbvz) = afuhpmqeao pgfwkgeqvx (dzoolgbdoo, blfeynssrr - ttzycnrbjr) View more
NCT04718103 (SWIFT-2, CTgov)	Phase 3	Asthma	397	GSK3511294 (GSK3511294)	rxpcrjtbyh(nxahhxzopv) = okgzmicdhc czornavmxs (gxtxoizquw, vydlztdmdv - amsrzfzveo) View more	-	29 Nov 2024
				Placebo (Placebo)	rxpcrjtbyh(nxahhxzopv) = zrkowwcqag czornavmxs (gxtxoizquw, ruaxuwtera - rycjnonjgz) View more
NCT04719832 \| NCT04718103 (SWIFT-1, Pubmed \| Biospace \| N Engl J Med) Manual	Phase 3	Severe asthma	792	depemokimab (SWIFT-1)	fuenvimjgv(vsajvxkrxj) = xifbzmpieh eegwgjpijy (mxucqmmelv, 0.36 - 0.58)	Positive	09 Sep 2024
				Placebo (SWIFT-1)	fuenvimjgv(vsajvxkrxj) = tlhenxaplk eegwgjpijy (mxucqmmelv, 0.86 - 1.43)
NCT04719832 (SWIFT-1, ERS2024)	Phase 3	Asthma	2,963	Depemokimab	zfgzjrgnqh(ornxwdcscs) = sviaqhlrcw nhzclkvxdr (daikxuaysb ) View more	Positive	07 Sep 2024
				Placebo	zfgzjrgnqh(ornxwdcscs) = okfpjgebvt nhzclkvxdr (daikxuaysb ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis